Afleveringen
-
What do you need to know about a once daily GLP-1 RA therapy for adults with T2D? Join experts in T2D Aaron King, MD, Helen Baron, MD, and Stephen Brunton, MD, FAAP, FRACGP, CDCES, as they discuss frequently asked questions regarding the use of a once daily treatment for adults with T2D with the goal of helping to provide answers. Key topics include dosing and administration, handling and storage, as well as efficacy and safety.
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
Aaron King, MD
Physician
Baptist Health System Physicians
San Antonio, TXHelen L. Baron, MD
Medical Director, Diabetes Services
Eisenhower Diabetes and Endocrinology
Montrose, CAStephen Brunton, MD, FAAFP, CDCES
Executive Director
Primary Care Metabolic Group
Winnsboro, SC -
What is the role of the pharmacist in patient-centered care of adults with type 2 diabetes (T2D)? Join pharmacist experts in T2D Jennifer Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP, Melody Hartzler, PharmD, BCACP, BC-ADM, AE-C, and Donald Nuzum, PharmD, BCACP, BC-ADM, CDCES, as they discuss education of patients and pharmacists on the pharmacokinetics, administration, dosing schedule and handling of a GLP-1 receptor agonist (GLP-1 RA). They will also consider when to use a GLP-1 RA, where they review clinical data on efficacy and safety of a GLP-1 RA, including in a trial when used as monotherapy vs placebo, a head-to-head study vs a DPP-4 inhibitor, and a cardiovascular outcomes study.
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
Jennifer D. Goldman, PharmD, CDCES, BC-ADM, FCCP
Professor of Pharmacy Practice & Clinical Pharmacist, Director of Cardiometabolic Services
Massachusetts College of Pharmacy and Health Sciences, Boston, MA; Well Life Medical, Peabody, MAMelody L. Hartzler, PharmD, BCACP, BC-ADM
Clinical Pharmacist & CEO
PharmToTable, LLC
Centerville, OHDonnie Nuzum, PharmD, BCACP, BC-ADM, CDCES
Associate Professor of Pharmacy, Clinical Pharmacist
Wingate University, Avance Primary Care
Indian Trail, North CA -
Zijn er afleveringen die ontbreken?
-
Explore a treatment option to improve glycemic control in adults with T2D and when you should consider using a GLP-1 RA. Join experts in T2D Aaron King, MD, Davida Kruger, MSN, APRN-BC, and Javier Morales, MD, as they review the disease state of T2D, the role of GLP-1 in glucose regulation, guidelines on early use of GLP-1 RAs in T2D treatment, as well as dosing, administration, and the monotherapy data of a once daily GLP-1 RA for T2D treatment.
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
Aaron King, MD
Physician
Baptist Health System Physician
San Antonio, TXDavida F. Kruger, MSN, APRN‐BC, BC‐ADM
Certified Nurse Practitioner
A Henry Ford Health System,
Division of Endocrinology, Diabetes,
Bone and Mineral Disorders
Detroit, MIJavier Morales, MD, FACP, FACE
Associate Clinical Professor of Medicine
Hofstra Northwell
Huntington, NY -
How common is treatment inertia in the treatment of adult patients with T2D and what can be done about it? Join a multidisciplinary panel including Jim Gavin, MD, PhD; Steve Vacalis, DO; and Jodi Strong, DNP, CDE, BC-ADM, CPT as they discuss and share their insights on the issues surrounding therapeutic inertia. They will also evaluate when to use a GLP-1 RA, and a clinical trial comparing the efficacy and safety of a GLP-1 RA versus a DPP-4i.
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
James R. Gavin III, MD, PhD
Clinical Professor of Medicine, Emory University
Chief Medical Officer, Healing Our Village, Inc.
Atlanta, GeorgiaJodi Strong, DNP, CDCES, BC-ADM, CPT
Aspirus Medical Group
Stevens Point, WisconsinSteve Vacalis, DO
Senior Lead Physician
CaroMont Family Medicine, CaroMont Regional Medical Center
Gastonia, North Carolina -
What do you need to know about a once-daily GLP-1 RA and what can you do to help your patients taking this T2D therapy? Join this multidisciplinary discussion with Jim Gavin, MD; Curtis Triplitt, PharmD; and Jeffrey Unger, MD, as they review the mechanism of action, dosing, efficacy, and safety of a once-daily GLP-1 RA for adult patients with T2D.
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
James R. Gavin III, MD, PhD
Clinical Professor of Medicine, Emory University
Chief Medical Officer, Healing Our Village, Inc.
Atlanta, GeorgiaJeff Unger, MD, FAAFP, FACE
Diplomate, American Board of Family Practice
Assistant Clinical Professor of Family Medicine, UC Riverside School of Medicine
Riverside, California
Director, Unger Concierge Primary Care Medical Group
Rancho Cucamonga, CaliforniaCurtis L. Triplitt, PharmD, CDCES, FADCES
Clinical Associate Professor of Medicine Division of Diabetes
University of Texas Health at San Antonio
Texas Diabetes Institute, part of the University Health System
San Antonio, Texas -
Join leaders in the field of diabetes Dr. Jim Gavin, Dr. Pablo Mora, and Dr. Bob Busch as they navigate through a clinical study. What do you need to know about using a GLP-1 RA for glycemic control with patients who have T2D? Are there any considerations for specific populations such as those who have moderate renal impairment?
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
James R. Gavin III, MD, PhD
Clinical Professor of Medicine, Emory University
Chief Medical Officer, Healing Our Village, Inc.
Atlanta, GeorgiaRobert Busch, MD
Director of Clinical Research
Albany Med Faculty Practice, Community Endocrine Group
Albany, New YorkPablo F. Mora, MD, FACE, MSc, CDCES
Endocrinologist, North Texas Diabetes & Endocrinology
Clinical Professor, Division of Endocrinology at University of Texas Southwestern Medical Center
Dallas, Texas
